Equity Overview
Price & Market Data
Price: $1.79
Daily Change: $0.00 / 0.00%
Range: $1.72 - $1.82
Market Cap: $83,541,984
Volume: 58,085
Performance Metrics
1 Week: 4.68%
1 Month: -0.56%
3 Months: -18.64%
6 Months: -51.49%
1 Year: -32.45%
YTD: 5.29%
Company Details
Employees: 69
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain in the United States. The company's lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. It also developing VG-3927, an orally available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Watertown, Massachusetts.